Evolent Health Announces $140M Convertible Note Offering and Discloses DOJ Investigation

Evolent Health, Inc.

Evolent Health intends to offer $140.0M aggregate principal amount of convertible senior notes due 2031, with an option for an additional $20.0M.
The company plans to use up to $100M of net proceeds to repurchase a portion of its 1.50% convertible senior notes due 2025 and about $40M to repurchase shares of its Class A common stock.
Evolent disclosed it received a Civil Investigative Demand from the DOJ on August 12, 2025, regarding a False Claims Act investigation involving former customer's diagnosis codes since 2016.
The notes will be convertible into cash, stock, or a combination, subject to conversion rights termination conditions after August 20, 2026.
The offering is private under Rule 144A, and the securities are not registered under the Securities Act.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.